Page last updated: 2024-11-04

alkannin and Coronavirus Infections

alkannin has been researched along with Coronavirus Infections in 1 studies

Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Jin, Z1
Du, X1
Xu, Y1
Deng, Y1
Liu, M1
Zhao, Y1
Zhang, B1
Li, X1
Zhang, L1
Peng, C1
Duan, Y1
Yu, J1
Wang, L1
Yang, K1
Liu, F1
Jiang, R1
Yang, X2
You, T1
Liu, X2
Bai, F1
Liu, H1
Guddat, LW1
Xu, W1
Xiao, G1
Qin, C1
Shi, Z1
Jiang, H1
Rao, Z1
Yang, H1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients[NCT04484025]Phase 260 participants (Anticipated)Interventional2021-10-12Enrolling by invitation
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients[NCT04483973]Phase 260 participants (Anticipated)Interventional2021-08-27Enrolling by invitation
DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130]Phase 211 participants (Actual)Interventional2021-08-18Terminated (stopped due to Low COVID case numbers, competing COVID treatments available)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in COVID-19 Symptom Severity Score as Assessed by a 5-point Adapted Somatic Symptom Severity Score (SSS-8)

"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31

Interventionunits on a scale (Median)
Cohort 1: Disulfiram-2.60
Cohort 1: Placebo-2.14

Virologic Impact of 5 Days of Disulfiram, as Measured by the Change in Copies of SARS-CoV-2 Virus Per mL Between Baseline and Day 31.

Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31

Interventioncopies/mL (Mean)
Cohort 1: Disulfiram 1000 mg-20.89
Cohort 1: Placebo-20

Immunologic Impact of 5 Days of Disulfiram, as Measured by the Fold-change in Plasma Levels of Pro-inflammatory Cytokines (e.g, Interleukin 6, Interleukin 1-beta, Etc.).

Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31

,
Interventionfold change (Median)
Change in IL-6 (pg/mL) Day 0 to 31Change in IL-1B (pg/mL) Day 0 to 31
Cohort 1: Disulfiram 100 mg-0.1186-0.1402
Cohort 1: Placebo-0.02150.0268

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31

,
InterventionParticipants (Count of Participants)
AE Grade 3 or HigherAE Grade 1 or 2
Cohort 1: Disulfiram 1000 mg04
Cohort 1: Placebo11

Other Studies

1 other study available for alkannin and Coronavirus Infections

ArticleYear
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020
Structure of M
    Nature, 2020, Volume: 582, Issue:7811

    Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections

2020